techcentury.com
Esperion Sets Phase 2 Study Of Cholesterol Buster Combo
ANN ARBOR — Esperion Therapeutics Inc. (NASDAQ:ESPR), the Ann Arbor-based pharmaceutical startup, announced the initiation of a Phase 2 clinical study (1002-039) to assess the efficacy and sa…